Weight loss of more than 11.5% in 12 weeks of administration! The results of the Phase 1 study of Innovent GLP-1R/GCGR dual agonists were published

The study published online is a randomized, placebo-controlled clinical study
evaluating the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of multiple dose escalation of Mazdutide in overweight or obese subjects in China.
Low-dose (3 mg, 4.
5 mg, and 6.
0 mg) cohort results were published in The Lancet in 2021
.
Results from the high-dose (9 mg and 10 mg) cohorts
are presented this time.
A total of 24 overweight or obese subjects were enrolled in the high-dose cohort, and 12 subjects in each cohort were randomized to receive a mazdutide dose titration of 2.
5-5.
0-7.
5-10.
0 mg or 3.
0-6.
0-9.
0 mg in a 2:1 ratio or placebo, administered subcutaneously once a week for 4 weeks
at each dose level.

The results of the study showed that Mazdutide titrated to 10 mg and 9 mg was well tolerated, and no participants withdrew from the study
due to adverse events.
No serious adverse events or severe adverse events
occurred.
The most commonly reported adverse events during the treatment period were gastrointestinal adverse events, the vast majority of which were mild
.
After 16 weeks of dosing, subjects treated with Mazdutide in the 10 mg cohort lost an average of 7.
62 kg from baseline (9.
5% reduction); After 12 weeks of dosing, subjects treated with Mazdutide in the 9 mg cohort lost an average of 9.
23 kg (11.
7% decrease)
from baseline.
Improvements in BMI and waist circumference, as well as metabolic markers such as blood pressure, lipids, and blood uric acid, in subjects treated with mazdutide were consistent
with trends observed in low-dose cohorts.